Predicting lung inflammation from radiation and immunotherapy
Part of Cancer, Injuries & trauma, Lungs & breathing clinical trials.
This study looks at using blood and imaging markers to predict if patients with lung cancer who receive both immunotherapy and chest radiation will develop lung inflammation (called radiation lung injury). It may help doctors personalise care and reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a life expectancy of at least 6 months.
- You must have good performance status (able to do most daily activities without much help).
- You must have a CT scan of your chest done before starting immunotherapy.
- You must have had at least 2 cycles of immunotherapy (PD-1 inhibitors) within the last 6 months.
- You must be planning to receive radiation therapy to the chest at a dose of at least 30 Gy, and you must not take antibiotics for 1 week before that radiation starts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood and sputum (phlegm) samples from people with lung cancer before and during immunotherapy. The goal is to see if certain immune markers in these samples can predict how well the treatment works.
This trial tests adding targeted radiation before standard immunotherapy and chemotherapy for people with stage 2-3 non-small cell lung cancer that can be surgically removed. The goal is to see if the radiation helps shrink the tumor more before surgery.
This trial looks at adding two immunotherapy drugs to radiation and chemotherapy for people with stage 3 lung cancer that cannot be removed by surgery. It compares giving immunotherapy during radiation versus giving it after radiation, to see which way may help control the cancer better.
This study looks for signs in the blood that can tell if a lung cancer patient is developing a side effect called pneumonitis (lung inflammation) from checkpoint inhibitor treatment. It may help doctors catch and treat this side effect early.
This study monitors how the heart and lungs respond to radiation therapy combined with immunotherapy for locally advanced lung cancer. It aims to learn how well patients tolerate treatment and to detect early signs of side effects.
This study looks for early “predictive markers” to tell who is most likely to develop lung inflammation after standard treatment for non-small cell lung cancer. It may help clinicians spot problems sooner and tailor care, using additional monitoring during treatment.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.